News of Note—NIH Zika vaccine trial, VBI Vaccines and more


Here is some other vaccine news of note for the week:

> The National Institutes of Health started a first-in-human study of a NIAID-developed live attenuated Zika virus vaccine candidate. Release

> VBI Vaccines appointed Christopher McNulty as its chief financial officer and head of business development. Release

> The Securities and Exchange Commission decided against further action after an investigation into possible securities law violations at Sinovac. Release

> BiondVax has moved manufacturing for its universal flu vaccine candidate to a new facility in the Jerusalem Bio Park. Release

Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.